FDA Publishes Complex Generics News Resource

August 5, 2022

Today the FDA is publishing a new web page to share the most recent FDA actions and activities related to complex generics. This new resource is part of FDA’s continued commitment to ensuring Americans have access to safe, effective, high-quality, and more affordable generic drugs.

Given FDA’s focus on regulatory and scientific initiatives to expand and strengthen this important area of our nation’s public health system, this page will be updated regularly with information about recent Agency actions related to complex generics, including:

  • notable approvals
  • guidance documents
  • research
  • events

Since these products are generally harder to develop, fewer exist, resulting in less market competition. This means that complex generics may be more expensive and less accessible to the patients who need them. Complex generics are a key component of FDA’s Drug Competition Action Plan, which aims to bring more drug competition to the market and address the high cost of medicines, and the Generic Drug User Fee Amendments, which include special provisions related to complex generics.

Complex Generics News Webpage

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.


August 30, 2017

Critical Components of Quality Management Systems

Critical Components of Quality Management Systems: In 1962, Congress instructed the FDA to require that all drugs be produced according to Good Manufacturing Practice (GMP), which must be compliant...

March 30, 2022

Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals

March 29, 2022 Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain...

April 26, 2022

Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children

April 25, 2022 Today, the U.S. Food and Drug Administration expanded the approval of the COVID-19 treatment Veklury (remdesivir) to include pediatric patients 28 days of age and older weighing at...